Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03981380 · ClinicalTrials.gov registry record
11C-PIB PET Study in MESA at Columbia University
A clinical trial of Alzheimer Disease and Cognitive Impairment, sponsored by José A. Luchsinger.
- Completed
- Registry status
- 59
- Enrollment target
- 1
- Study location
NCT03981380: Completed study of Alzheimer Disease and Cognitive Impairment, sponsored by José A. Luchsinger.
NCT03981380 is a study of Alzheimer Disease and Cognitive Impairment that has completed, run by José A. Luchsinger. The registered enrollment target is 59 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03981380, a study of Alzheimer Disease and Cognitive Impairment, has completed, sponsored by José A. Luchsinger.
- COMPLETED
- Registry status
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will conduct a study of brain positron emission tomography (PET) using 11C-PIB for the imaging of brain amyloid in 250 participants in the Multiethnic study of atherosclerosis (MESA) at Columbia University Irving Medical Center in New York City. Participants will be imaged only once with Pittsburgh Compound B (PIB) PET.
Primary Outcome
Standardized uptake value ratio (SUVR) of 11C-PIB;The extent of Aβ deposition in the brain will be quantified by\[11C\]PiB uptake visualized by PET using standardized uptake volume ratio (SUVR) of 6 primary cortical areas (i.e., anterior cingulate, prefrontal cortex, lateral temporal cortex, posterior parietal cortex, precuneus cortex, and anteroventral striatum) relative to the uptake in the cerebellum
Conditions Studied
Interventions
- DRUG 11C-PIB
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2020-08-01 |
| Est. Completion | 2024-02-05 |
What the finished NCT03981380 record still lists
NCT03981380 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which 11C-PIB is the first listed.
NCT03981380 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03981380 about?
NCT03981380 is a clinical study titled "11C-PIB PET Study in MESA at Columbia University". The investigators will conduct a study of brain positron emission tomography (PET) using 11C-PIB for the imaging of brain amyloid in 250 participants in the Multiethnic study of atherosclerosis (MESA) at Columbia University Irving Medical Center in New York City. Participants will be imaged only onc...
What is the current status of trial NCT03981380?
This trial is currently completed. The enrollment target is 59 participants. The study started on 2020-08-01. Estimated completion is 2024-02-05.
What conditions does trial NCT03981380 study?
This clinical trial studies the following conditions: Alzheimer Disease, Cognitive Impairment, Atherosclerosis, Vascular Diseases.
What interventions are being tested in trial NCT03981380?
The interventions under investigation include: 11C-PIB (DRUG).
Who is sponsoring clinical trial NCT03981380?
This trial is sponsored by José A. Luchsinger, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03981380 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03981380's enrollment target sits among peer trials
59 200th of 306 higher than 107 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI